Compare AUPH & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | INDV |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 4.1B |
| IPO Year | 1999 | N/A |
| Metric | AUPH | INDV |
|---|---|---|
| Price | $15.75 | $35.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.25 | ★ $32.50 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.55 | ★ 0.98 |
| Revenue | $265,808,000.00 | ★ $1,180,000,000.00 |
| Revenue This Year | $21.22 | $1.09 |
| Revenue Next Year | $15.40 | N/A |
| P/E Ratio | ★ $28.81 | $36.24 |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $7.62 |
| 52 Week High | $16.48 | $38.00 |
| Indicator | AUPH | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 67.20 |
| Support Level | $15.15 | $35.40 |
| Resistance Level | $16.03 | $36.55 |
| Average True Range (ATR) | 0.50 | 0.95 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 57.02 | 50.74 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.